Novavax: High Probability Of A Huge Gain Within Weeks - Part 1 Of 2

Novavax (NASDAQ:NVAX) is on the verge of a probable FDA approval of its vaccine to prevent RSV (respiratory syncytial virus) infection in older adults. The company has said that results of its Phase 3 clinical trial named Resolve will be announced by the end of this quarter, which ends September 30th.

The Prevalence and Impacts of RSV

There is currently no vaccine for RSV. As the CDC's website explains, RSV...

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect